Stockreport

Phase III PALLAS Study Shows Signatera™ MRD Testing Provides Powerful Post-Surgical Prognostic Information in Patients with High and Intermediate Risk HR+/HER2- Breast Cancer [Yahoo! Finan...

Natera, Inc.  (NTRA) 
Last natera, inc. earnings: 2/26 04:10 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.natera.com
PDF AUSTIN, Texas, December 11, 2025 BUSINESS WIRE )--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, together with Alliance Foundation [Read more]